Drug Profile
Cancer vaccine - Intercell AG
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Intercell
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bladder cancer; Malignant melanoma
Most Recent Events
- 31 Dec 2003 Discontinued - Phase-I for Bladder cancer in Austria (unspecified route)
- 31 Dec 2003 Discontinued - Phase-I for Malignant melanoma in Austria (unspecified route)
- 20 Aug 2003 Phase-I clinical trials in Bladder cancer in Austria (unspecified route)